Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mechanisms Preserving Insulin Action during High Dietary Fat Intake

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic Determinants of Weight Loss After Bariatric Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pathogenic mutations in the appetite-regulating melanocortin-4 receptor (MC4R) represent the most common cause of monogenic obesity with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause weight loss by reducing appetite. We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8). Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations and by 6.1 kg ± 1.2 kg in control participants. Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups. Thus, liraglutide induced an equal, clinically significant weight loss of 6% in both groups, indicating that the appetite-reducing effect of liraglutide is preserved in MC4R causal obesity and that liraglutide acts independently of the MC4R pathway. Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity.

OriginalsprogEngelsk
TidsskriftCell Metabolism
Vol/bind28
Udgave nummer1
Sider (fra-til)23-32
ISSN1550-4131
DOI
StatusUdgivet - 1 aug. 2018

ID: 54585372